Thursday, 12 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 27, 2026

Finland Prepaid Card and Digital Wallet Market Intelligence Report 2026-2030: Edenred and ePassi Compete on App-Led Usability While Enfuce Strengthens Modular Card Issuing

View original at globenewswire.com
Finland Prepaid Card and Digital Wallet Market Intelligence Report 2026-2030: Edenred and ePassi Compete on App-Led Usability While Enfuce Strengthens Modular Card Issuing Dublin, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Paper lunch and culture vouchers will be discontinued with use allowed through 2026

    80% confidence
  • Nordic and Estonia plan to implement offline card payment back-ups, with Finland intending to offer offline options and a national instant-payment platform

    80% confidence
  • The prepaid card and digital wallet market in Finland achieved a CAGR of 11.3% during 2021-2025

    80% confidence
  • The value of contactless payments rose 23% year-over-year to EUR 8.4 billion in Q2 2025

    80% confidence
  • The market is forecast to grow at a CAGR of 6.5% during 2026-2030, expanding from USD 3.79 billion in 2025 to approximately USD 5.25 billion by end of 2030

    80% confidence
  • The Finland prepaid card and digital wallet market is expected to grow by 7.7% on annual basis to reach US$4.08 billion in 2026

    80% confidence
  • The most durable prepaid growth pockets in Finland over the next 2-4 years are expected to remain controlled-spend programs (employee benefits, targeted disbursements) and institutional/regulated use cases

    80% confidence
  • Apple Pay and Google Pay are enabled for benefits spending on Edenred Finland platform

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com